1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,200 | 8,600 | 26.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.04. | Elicio Therapeutics, Inc.: Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 05.04. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.03. | Elicio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 29.03. | Elicio Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 29.03. | Elicio Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | - | Reuters | ||
| 29.03. | Elicio Therapeutics GAAP EPS of -$6.96 | 1 | Seeking Alpha | ||
| 29.03. | Elicio Therapeutics, Inc.: Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates | 314 | GlobeNewswire (Europe) | ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the AACR... ► Artikel lesen | |
| 29.03. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | Elicio Therapeutics to sell 1.03M shares $5.81 in private placement financing | 1 | Seeking Alpha | ||
| 18.03. | Elicio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.03. | Elicio Therapeutics, Inc.: Elicio Therapeutics Announces $6.0 Million Private Placement Financing | 2 | GlobeNewswire (USA) | ||
| 06.03. | Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 21.02. | Elicio's vaccine shows promise as potential cancer treatment in phase 1 trial | 3 | PharmaTimes | ||
| 05.02. | Elicio Therapeutics Inc.: Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | 2 | GlobeNewswire (USA) | ||
| 05.02. | Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy | 1 | Benzinga.com | ||
| 02.02. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.01. | First Patient Dosed In Phase 2 Study Of Elicio Therapeutics' ELI-002 7P | 1 | Benzinga.com | ||
| 29.01. | Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002 | 1 | Benzinga.com | ||
| 25.01. | Elicio Therapeutics Inc.: Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors | 190 | GlobeNewswire (Europe) | Published data shows lymph node-targeted Amphiphile ("AMP")-peptide and CpG combination with TCR-T cell therapy led to complete eradication and durable responses against established murine solid tumors... ► Artikel lesen | |
| 17.01. | Elicio Therapeutics Inc.: Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium | 1 | GlobeNewswire (USA) |
Seite:
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,545 | -5,21 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| NANOREPRO | 1,845 | -0,27 % | EQS-News: NanoRepro AG: Veröffentlichung von Kapitalmarktinformationen | EQS-News: NanoRepro AG
/ Schlagwort(e): Aktienrückkauf
NanoRepro AG: Veröffentlichung von Kapitalmarktinformationen
22.04.2024 / 12:00 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| OCUGEN | 1,180 | -1,01 % | Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards? | ||
| SCORPIUS | 0,150 | -6,25 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Receipt of Filing Delinquency Notification | DURHAM, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), received an official notice... ► Artikel lesen | |
| AETERNA ZENTARIS | 1,810 | 0,00 % | Aeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris | TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro") are pleased to announce... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,860 | +1,18 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 3,883 | -0,03 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2024 Financial Results on May 6 | ||
| VIKING THERAPEUTICS | 68,84 | -0,86 % | Viking Therapeutics: So lief das erste Quartal | Viking Therapeutics hat im ersten Quartal 2024 finanzielle und operative Verbesserungen verzeichnet, die über den Markterwartungen liegen. Trotz der Herausforderungen in der Biopharmabranche blieb das... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,401 | -0,25 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| VAXART | 0,619 | -6,71 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the"Company"or"Vaxart") today announced that the Compensation Committee of the Board of Directors approved... ► Artikel lesen | |
| IBIO | 1,770 | +3,51 % | Pre-market Movers: iBio, Direct Digital Holdings, Nuvation Bio, PaySign, LuxUrban Hotels | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.30 A.M. ET).In the Green iBio, Inc. (IBIO) is up over 86% at $2.14.
Nuvation... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,546 | -0,08 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update | On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical trial... ► Artikel lesen | |
| ALDEYRA | 3,715 | +1,25 % | Aldeyra Therapeutics, Inc. - 8-K, Current Report | ||
| GINKGO BIOWORKS | 0,860 | +10,30 % | Looking Into Ginkgo Bioworks Holdings' Recent Short Interest | ||
| MANNKIND | 3,884 | +2,13 % | MannKind Announces CFO Transition | Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024, through December 31, 2024Christopher Prentiss appointed Chief Financial... ► Artikel lesen |
Das Unternehmen ELICIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 8,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
